Alpha Tau Medical (DRTS) director discloses shares, RSUs and options

Rhea-AI Filing Summary

Alpha Tau Medical Ltd. director Blumenfeld S. Morry filed an initial Form 3 reporting his existing equity position. He directly holds 155,771 Ordinary Shares of Alpha Tau Medical and 4,680 Restricted Share Units, which will vest in full on the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to his continued service.

He also reports multiple option grants over Ordinary Shares at exercise prices ranging from $2.98 to $11.50 per share, with expirations between 2028 and 2036. Footnotes indicate that some options are already fully vested, while others will vest in their entirety on the same schedule tied to March 9, 2026 or the next Annual General Meeting.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Blumenfeld S Morry

(Last) (First) (Middle)

C/O ALPHA TAU MEDICAL

PO BOX 45044

(Street)

JERUSALEM 9777605

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Alpha Tau Medical Ltd. [ DRTS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	155,771	D
Restricted Share Units(1)	4,680	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options(2)	03/01/2019	11/26/2028	Ordinary Shares	54,318	$4.42	D
Options(2)	06/07/2022	08/08/2031	Ordinary Shares	24,727	$11.5	D
Options(2)	11/02/2022	03/21/2032	Ordinary Shares	8,945	$10.92	D
Options(2)	11/02/2022	06/02/2032	Ordinary Shares	10,657	$7.19	D
Options(2)	01/01/2024	03/09/2033	Ordinary Shares	46,905	$3.28	D
Options(2)	12/17/2024	03/07/2034	Ordinary Shares	43,257	$2.98	D
Options(2)	06/17/2025	01/22/2035	Ordinary Shares	24,460	$4.05	D
Options(3)	(3)	03/09/2036	Ordinary Shares	15,527	$6.41	D

Explanation of Responses:

1. These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.

2. These are options to acquire ordinary shares, which have fully vested as of the date hereof.

3. These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.

	/s/ Samuel Morry Blumenfeld	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Alpha Tau Medical (DRTS) director Blumenfeld S. Morry report in this Form 3?

The Form 3 shows Blumenfeld S. Morry’s initial equity holdings in Alpha Tau Medical. He reports direct ownership of ordinary shares, restricted share units, and several stock option grants, establishing his baseline beneficial ownership as a director.

How many Alpha Tau Medical (DRTS) ordinary shares does the director hold?

Blumenfeld S. Morry reports holding 155,771 Ordinary Shares of Alpha Tau Medical. This figure reflects his direct ownership as of the Form 3 filing date and serves as the starting point for tracking any future changes in his share position.

What restricted share units are disclosed for Alpha Tau Medical (DRTS) in this filing?

The director holds 4,680 Restricted Share Units. According to the footnotes, these RSUs vest in full on the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, provided he continues to serve the company.

What stock options does the Alpha Tau Medical (DRTS) director report owning?

He reports several option grants over Alpha Tau Medical ordinary shares, with exercise prices ranging from $2.98 to $11.50 per share. Expiration dates span from 2028 through 2036, giving him long-dated potential to acquire additional shares.

Are any of the Alpha Tau Medical (DRTS) options already vested for the director?

Yes. A footnote states that some options to acquire ordinary shares are fully vested as of the filing date. Another footnote explains that additional options will vest in full on the earlier of one year from March 9, 2026 or the next Annual General Meeting.

Does this Alpha Tau Medical (DRTS) Form 3 show any insider buying or selling?

No new market trades are indicated. The filing classifies the entries as holdings, with transaction summaries showing no buys or sells. It primarily establishes the director’s existing ownership of shares, RSUs, and options rather than reporting fresh purchases or sales.